Sponsor: University of Copenhagen, Department of Haematology, Herlev Hospital
Principal investigator: Hans Carl Hasselbalch
Primary objective: To quantify JAK2 mutation allele burden at diagnosis and after interferon therapy in a large cohort (approximately 100) patients with PV. ET and PMF. To corroborate a high correlation between JAK2 mutation allelle burden in bone marrow and peripheral blood in patients with a low allele burden.
Status: 90 patients included in Denmark.
Start: Spring 2009.
Research support: Scering-Plough Denmark
Study design: Retrospective analysis of marrow samples at diagnosis are compared to samples obtained after or during interferon therapy. All JAK2 analyses are done centrally.
Contact person: Hans Carl Hasselbalch